Cocaine Addiction
Conditions
Keywords
cocaine addiction treatment craving
Brief summary
The primary objective is to investigate the potential ability of Inderal (propranolol hydrochloride) to diminish the reconsolidation of motivationally potent drug-related cues in cocaine dependent participants. If effective in this laboratory model, Inderal may have clinical efficacy.
Interventions
DRUGInderal
Inderal vs. placebo will be administered with or without cocaine cues
Sponsors
McGill University Health Centre/Research Institute of the McGill University Health Centre
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* 60 psychotropic medication-free men or women (15 subjects x 4 groups) who have met DSM-IV-TR diagnostic criteria for cocaine dependence for the past 6 months (age 18 - 50 years old); * Minimum of three days cocaine abstinent on study days; * Primary use of cocaine is intra-nasal or smoked crack
Exclusion criteria
* Medical conditions that might be aggravated by participation in the study: * cardiovascular disorders that might be aggravated by participation in the study: hypotension (SBP: \< 100 mmHg), bradycardia (heart rate \< 60 /min), severe atrioventricular block (Type II or III), severe hypertension (SBP: \> 160 mmHg; DBP: \> 100 mmHg), myocardial infarction, history of chest pain and admission to ED for chest pain; * respiratory disorders: bronchial asthma and chronic obstructive pulmonary disease; * diabetic patients treated with insulin or oral hypoglycemic agents. Propranolol may mask the first signs of a developing hypoglycemia. * Seropositive pregnancy test * Comorbidity with current axis I psychiatric disorders other than anxiety, affective and substance use disorders * Severe liver disfunction * Current or recent (\< 5 half lives) use of medications that may interact with Inderal (see above) * Positive urine tox screen for barbiturates. Positive breath alcohol screen. {Note: all urine tox screen results will be destroyed immediately after collection. The information will not be stored}
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Self-report drug craving | One day and one month post-treatment | One day and one month after the intervention, the investigators will measure drug craving using visual analog scales (VAS) and the Cocaine Craving Questionnaire (CCQ). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Drug use | One month after the intervention | One month after the intervention, participants will be interviewed about their drug and alcohol use |
Outcome results
None listed